/ Print /

Drug costs

When given the chance, will patients choose cheaper prescription drugs?A new UC Berkeley study has surprising findings about reference pricing and patient drug selection.
How to approach value in oncologyAn eye-opening study by Precision for Value assesses cancer value frameworks.
Top 3 factors in biosimilar coverageAn Avalere study has interesting findings about payer acceptance of biosimilars.
ICER, VA join to work on drug value, price negotiationsAnalysts discuss how pharmacoeconomics will make a difference in treatment decisions.
Opinion: Top 2 takeaways from UBS Global Healthcare ConferenceThe conference raised important points about unregulated growth opportunities and new pharmacy arena players.
What's missing in hep C drugsPayers have unmet needs in the changing hepatitis C (HCV) space, according to a recent survey. The survey, from Precision for Value, highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.
Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
Payers to pharma: Here’s what we’re missing in hep C drugsA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Top challenges in cancer careCancer drug costs remain the most critical challenge in care, among other things.